1. Home
  2. KOSS vs CTSO Comparison

KOSS vs CTSO Comparison

Compare KOSS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$4.58

Market Cap

43.6M

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.68

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
CTSO
Founded
1953
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.6M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KOSS
CTSO
Price
$4.58
$0.68
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
23.6K
114.9K
Earning Date
01-29-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,493,080.00
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
11.58
23.89
52 Week Low
$4.00
$0.60
52 Week High
$8.59
$1.61

Technical Indicators

Market Signals
Indicator
KOSS
CTSO
Relative Strength Index (RSI) 43.00 43.59
Support Level $4.56 $0.66
Resistance Level $4.86 $0.76
Average True Range (ATR) 0.19 0.07
MACD -0.01 -0.00
Stochastic Oscillator 4.00 24.33

Price Performance

Historical Comparison
KOSS
CTSO

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: